Journal: Nature Materials

Article Title: Parenchymal and stromal tissue regeneration of tooth organ by pivotal signals reinstated in decellularized matrix

doi: 10.1038/s41563-019-0368-6

Figure Lengend Snippet: Fig. 4 | Alx3-restored adult MSC-induced angiogenesis and VEGF signalling. a,d, Angiogenesis in regenerated tissues with magnifications. d, native dentin. b,e, Human von Willebrand factor immunohistochemistry with magnifications. Green arrowheads, endothelial cells of human origin (e); black arrowheads, endothelial cells of host (mouse) origin (e); red arrowheads chimeric blood vessels (e). c,f, Human mitochondria staining; red arrowheads, human cells; black arrowheads, host (mouse) cells. a–f, n = 5 independent biological samples. g, Blood vessel (bv) quantification. n = 5 independent biological samples, presented as the mean ± s.d. P values calculated by one-way ANOVA with Bonferroni: **P < 0.01, ***P < 0.001. h, CCK8 of HUVECs treated with conditioned medium (CM) by vector control or Alx3-restored MSCs. n = 4 independent biological samples, presented as the mean ± s.d. P values calculated by one-way ANOVA with Bonferroni: *P < 0.05). i–o, Transwell migration assay by Alx3 conditioned medium or with neutralizing antibody or VEGFR2 inhibitor (i–n) and quantification (o). n = 4 independent biological samples, presented as mean ± s.d. P values calculated by one-way ANOVA with Bonferroni: *P < 0.05, **P < 0.01, ***P < 0.001). p, Mouse VEGF A promoter luciferase reporter with two Alx3-binding elements in the dashed red boxes (left) and VEGF luciferase assay on Alx3 transfection (right). n = 3 independent biological samples, presented as median with range. P values calculated by Kruskal–Wallis tests: *P < 0.05). BE, binding element. q,r, VEGF production and p-VEGFR2 activation by western blot (q) and quantification (r). n = 4 independent biological samples, presented as the mean ± s.d. P values calculated by one-way ANOVA with Bonferroni: *P < 0.05, **P < 0.01, ***P < 0.001. s–x: The tube formation of HUVECs treated by Alx3 conditioned medium with or without NAb or VEGFR2 inhibitor. n = 3 independent biological samples. y, Tube length quantification. n = 3 independent biological samples, presented as the median with range. P values calculated by Kruskal–Wallis tests: *P < 0.05, **P < 0.01. z, rtPCR of VE-cadherin, PECAM1, VEGF and Flk1. n = 4 independent biological samples, presented as the mean ± s.d. P values calculated by one-way ANOVA with Bonferroni: *P < 0.05, **P < 0.01, ***P < 0.001).

Article Snippet: The 1.6 kB VEGF luc plasmid was a gift from P. D’Amore (Addgene plasmid no. 29667).

Techniques: Immunohistochemistry, Staining, Plasmid Preparation, Control, Transwell Migration Assay, Luciferase, Binding Assay, Transfection, Activation Assay, Western Blot, Reverse Transcription Polymerase Chain Reaction

Journal: Frontiers in Immunology

Article Title: A Novel Sample Selection Approach to Aid the Identification of Factors That Correlate With the Control of HIV-1 Infection

doi: 10.3389/fimmu.2021.634832

Figure Lengend Snippet: Descriptive statistics for all the proteins assessed.

Article Snippet: Fifty-two soluble analytes were quantified in plasma using a combination of six Meso Scale Discovery (MSD) human V-PLEX panels including the Angiogenesis Panel 1 (VEGF-A, VEGF-C, VEGF-D, Tie-2, Flt-1, PIGF, bFGF), TH17 Panel 1 (IL-17A, IL-21, IL-31, IL-27, IL-23, IL-22, MIP-3α), Chemokine Panel 1 (Eotaxin, MIP-1β, Eotaxin-3, TARC, IP-10, MIP-1α, IL-8, MCP-1, MDC, MCP-4), Cytokine Panel 1 (GM-CSF, IL-1α, IL-5, IL-7, IL-12/IL-23p40, IL-15, IL-16, IL-17A, TNF-β, VEGF-A), Cytokine Panel 2 (IL-1RA, IL-3, IL-9, IL-17A/F, IL-17B, IL-17C, IL-17D, TSLP), Proinflammatory Panel 1 (IFN-γ, IL-1β, IL-2, IL-4, IL-6, IL-8, IL-10, IL-12p70, IL-13, TNF-α), and Vascular Injury Panel 2 (SAA, CRP, VCAM-1, ICAM-1).

Techniques:

Journal: Translational Oncology

Article Title: Co-Expression of VEGF and IL-6 Family Cytokines is Associated with Decreased Survival in HER2 Negative Breast Cancer Patients: Subtype-Specific IL-6 Family Cytokine-Mediated VEGF Secretion 1 2

doi: 10.1016/j.tranon.2018.10.004

Figure Lengend Snippet: Increased co-expression of OSM or OSMRβ and VEGF correlates with decreased survival of IDC patients. Kaplan–Meier survival curves of invasive ductal breast carcinoma for A) OSM and VEGF (n = 318) and B) OSMRβ and VEGF expression (n = 389), as separated by quartiles. As co-expression of OSM and VEGF increases, overall survival trends decrease, with patients expressing high OSM high VEGF (upper quartiles, respectively) exhibiting significantly worse survival ( P = .0192) than individuals expressing low OSM low VEGF (lower quartiles, respectively). A comparable trend is observed with co-expression of OSMRβ and VEGF ( P = .0012). Analysis obtained from Oncomine dataset entitled Curtis Breast. Log-rank test * P < .05, ** P < .01.

Article Snippet: Analysis of VEGF secretion in the conditioned media (CM) of MDA-MB-231, T47D, MCF7, SK-BR-3, MDA-MB-453, and BT474 (ATCC, Manassas, VA) breast cancer cells was assessed via VEGF ELISA according to the manufacturer's protocol (Cat# Dy293B, R&D Systems, Bethesda, MD).

Techniques: Expressing

Journal: Translational Oncology

Article Title: Co-Expression of VEGF and IL-6 Family Cytokines is Associated with Decreased Survival in HER2 Negative Breast Cancer Patients: Subtype-Specific IL-6 Family Cytokine-Mediated VEGF Secretion 1 2

doi: 10.1016/j.tranon.2018.10.004

Figure Lengend Snippet: Inflammatory cytokine and VEGF co-expression are correlated with decreased survival of invasive ductal carcinoma patient. These Kaplan–Meier curves in Figure 1, A and B , are a subset of the data presented in . A) Kaplan–Meier survival curves of invasive ductal breast carcinoma patients with high OSM and VEGF expression (upper quartiles, respectively) present diminished survival when compared to individuals with low OSM and VEGF expression (lower quartiles, respectively). Comparable trends appear upon examination of the upper and lower quartiles of patients with B) OSMRβ and VEGF expression, C) IL-6 and VEGF expression, and D) IL-6Rα and VEGF expression, indicating significant differences between upper and lower quartile survival for each group. Survival of patients with invasive ductal breast carcinoma by E) LIF and VEGF expression and F) LIFRβ and VEGF expression are not significantly different. Analysis obtained from Oncomine dataset entitled Curtis Breast. Log-rank test * P < .05, ** P < .01, *** P < .001. Inflammatory cytokine and VEGF co-expression are correlated with decreased survival of invasive ductal carcinoma patient. These Kaplan–Meier curves in Figure 1, A and B , are a subset of the data presented in Supplemental Figure S1. A) Kaplan–Meier survival curves of invasive ductal breast carcinoma patients with high OSM and VEGF expression (upper quartiles, respectively) present diminished survival when compared to individuals with low OSM and VEGF expression (lower quartiles, respectively). Comparable trends appear upon examination of the upper and lower quartiles of patients with B) OSMRβ and VEGF expression, C) IL-6 and VEGF expression, and D) IL-6Rα and VEGF expression, indicating significant differences between upper and lower quartile survival for each group. Survival of patients with invasive ductal breast carcinoma by E) LIF and VEGF expression and F) LIFRβ and VEGF expression are not significantly different. Analysis obtained from Oncomine dataset entitled Curtis Breast. Log-rank test * P < .05, ** P < .01, *** P < .001.

Article Snippet: Analysis of VEGF secretion in the conditioned media (CM) of MDA-MB-231, T47D, MCF7, SK-BR-3, MDA-MB-453, and BT474 (ATCC, Manassas, VA) breast cancer cells was assessed via VEGF ELISA according to the manufacturer's protocol (Cat# Dy293B, R&D Systems, Bethesda, MD).

Techniques: Expressing

Journal: Translational Oncology

Article Title: Co-Expression of VEGF and IL-6 Family Cytokines is Associated with Decreased Survival in HER2 Negative Breast Cancer Patients: Subtype-Specific IL-6 Family Cytokine-Mediated VEGF Secretion 1 2

doi: 10.1016/j.tranon.2018.10.004

Figure Lengend Snippet: Co-expression of VEGF with OSM or OSMRβ appears to affect survival in HER2- but not HER2+ subtypes. A) Kaplan–Meier survival curves of invasive ductal breast carcinoma for HER2- patients and HER2+ patients by OSM and VEGF expression. In HER2- patients, high OSM and high VEGF expression (upper quartiles, respectively) is strongly correlated with decreased survival when compared to patients with low OSM and low VEGF expression (lower quartiles, respectively). However, this trend is not evident in HER2+ individuals, as no significant difference is observed between survival of patients with OSM and VEGF expression in upper and lower quartiles, respectively. Similar trends are observed in Kaplan–Meier survival curves for B) HER2- and HER2+ by OSMRβ and VEGF expression. Analysis obtained from Oncomine dataset entitled Curtis Breast. Log-rank test * P < .05, ** P < .01, *** P < .001.

Article Snippet: Analysis of VEGF secretion in the conditioned media (CM) of MDA-MB-231, T47D, MCF7, SK-BR-3, MDA-MB-453, and BT474 (ATCC, Manassas, VA) breast cancer cells was assessed via VEGF ELISA according to the manufacturer's protocol (Cat# Dy293B, R&D Systems, Bethesda, MD).

Techniques: Expressing

Journal: Translational Oncology

Article Title: Co-Expression of VEGF and IL-6 Family Cytokines is Associated with Decreased Survival in HER2 Negative Breast Cancer Patients: Subtype-Specific IL-6 Family Cytokine-Mediated VEGF Secretion 1 2

doi: 10.1016/j.tranon.2018.10.004

Figure Lengend Snippet: IL-6 family cytokine OSM induces VEGF secretion independent of HIF1α signaling in MDA-MB-231 cells. A) Treatment with OSM, IL-6, and LIF (25 ng/mL) for 24 hours promotes expression of HIF1α in MDA-MB-231 TNBC cells. Addition of an siRNA targeting HIF1α (siHIF1α) ablates the effect of adding cytokines. B) T47D cells treated with IL-6 family cytokines for 72 hours express greater levels of HIF1α relative to non-treated control. Treatment with siHIF1α reduces this effect, as assessed by immunoblot analysis. Immunoblots are representative of at least 3 experiments. Induction of VEGF secretion is observed following treatment with IL-6 family cytokines (25 ng/mL) for 24 hours in C) MDA-MB-231 cells (n = 5) and for 72 hours in D) T47D cells (n = 3), as determined by ELISA. Treatment with siHIF1α does not affect VEGF secretion in OSM-treated MDA-MB-231 cells; however, VEGF secretion is modestly reduced in T47D cells treated with OSM and siHIF1α. E) A panel of additional human breast cancer cell lines were tested for VEGF expression by ELISA. HER2- MCF7 cells have significant OSM-induced VEGF secretion, while HER2+ BT474, SK-BR-3, and MDA-MB-453 cells do not produce increased VEGF in response to OSM. One-way ANOVA, Tukey's post-test, ** P < .01, *** P < .001.

Article Snippet: Analysis of VEGF secretion in the conditioned media (CM) of MDA-MB-231, T47D, MCF7, SK-BR-3, MDA-MB-453, and BT474 (ATCC, Manassas, VA) breast cancer cells was assessed via VEGF ELISA according to the manufacturer's protocol (Cat# Dy293B, R&D Systems, Bethesda, MD).

Techniques: Expressing, Control, Western Blot, Enzyme-linked Immunosorbent Assay

Journal: Translational Oncology

Article Title: Co-Expression of VEGF and IL-6 Family Cytokines is Associated with Decreased Survival in HER2 Negative Breast Cancer Patients: Subtype-Specific IL-6 Family Cytokine-Mediated VEGF Secretion 1 2

doi: 10.1016/j.tranon.2018.10.004

Figure Lengend Snippet: OSM strongly induces phosphorylation of STAT3. A) Treatment with OSM (25 ng/mL) for 15 minutes, 30 minutes, and 1 hour strongly induces phosphorylation of STAT3 (Tyr 705) in MDA-MB-231 cells and moderately induces JNK phosphorylation (T183/Y185). Treatment with either IL-6 or LIF (25 ng/mL) does not induce pSTAT3 or pJNK. B) Treatment with OSM induces phosphorylation of STAT3 and JNK in T47D cells. IL-6 induces moderate phosphorylation of STAT3 and JNK at early time points. Phosphorylation of STAT3 and JNK was compared to control β-actin, as assessed by immunoblot analysis. Blots are representative of three experiments. Time course experiment for STAT3 phosphorylation upon treatment with OSM or IL-6 (25 ng/mL) for 0.25–72 hours in C) MDA-MB-231 cells, and in D) T47D cells. Treatment with IL-6 does not induce pSTAT3 expression in MDA-MB-231 cells, while inducing moderate pSTAT3 expression in T47D cells. ELISA was performed in quadruplicate; two-way ANOVA with Bonferroni post-test, * P < .05, ** P < .01, *** P < .001.

Article Snippet: Analysis of VEGF secretion in the conditioned media (CM) of MDA-MB-231, T47D, MCF7, SK-BR-3, MDA-MB-453, and BT474 (ATCC, Manassas, VA) breast cancer cells was assessed via VEGF ELISA according to the manufacturer's protocol (Cat# Dy293B, R&D Systems, Bethesda, MD).

Techniques: Phospho-proteomics, Control, Western Blot, Expressing, Enzyme-linked Immunosorbent Assay

Journal: Translational Oncology

Article Title: Co-Expression of VEGF and IL-6 Family Cytokines is Associated with Decreased Survival in HER2 Negative Breast Cancer Patients: Subtype-Specific IL-6 Family Cytokine-Mediated VEGF Secretion 1 2

doi: 10.1016/j.tranon.2018.10.004

Figure Lengend Snippet: OSM induces VEGF via STAT3 signaling. A) Treatment with OSM (25 ng/mL) and siSTAT3 suppresses VEGF secretion by 3-fold in MDA-MB-231 cells. B) Treatment with OSM and siSTAT3 moderately reduces VEGF secretion by T47D cells. VEGF secretion was not reduced by the addition of siRNAs targeting both JNK1 and JNK2 in either C) MDA-MB-231 or D) T47D cells. Experiments were performed in triplicate two-way ANOVA with Bonferroni post-test, * P < .05, *** P < .001.

Article Snippet: Analysis of VEGF secretion in the conditioned media (CM) of MDA-MB-231, T47D, MCF7, SK-BR-3, MDA-MB-453, and BT474 (ATCC, Manassas, VA) breast cancer cells was assessed via VEGF ELISA according to the manufacturer's protocol (Cat# Dy293B, R&D Systems, Bethesda, MD).

Techniques:

Journal: Translational Oncology

Article Title: Co-Expression of VEGF and IL-6 Family Cytokines is Associated with Decreased Survival in HER2 Negative Breast Cancer Patients: Subtype-Specific IL-6 Family Cytokine-Mediated VEGF Secretion 1 2

doi: 10.1016/j.tranon.2018.10.004

Figure Lengend Snippet: Mechanistically distinct regulation of VEGF secretion in MDA-MB-231 TNBC and T47D (ER+/PR+/HER2-) cells. A) The VEGF promoter can be activated by various transcription factors. B) In MDA-MB-231 cells, OSM mediates VEGF secretion by activating the STAT3 signaling pathway downstream of the OSMR (OSMRβ + gp130). In T47D cells, OSM regulates VEGF secretion via both HIF1α and the STAT3 signaling pathway.

Article Snippet: Analysis of VEGF secretion in the conditioned media (CM) of MDA-MB-231, T47D, MCF7, SK-BR-3, MDA-MB-453, and BT474 (ATCC, Manassas, VA) breast cancer cells was assessed via VEGF ELISA according to the manufacturer's protocol (Cat# Dy293B, R&D Systems, Bethesda, MD).

Techniques:

Journal: Translational Oncology

Article Title: Co-Expression of VEGF and IL-6 Family Cytokines is Associated with Decreased Survival in HER2 Negative Breast Cancer Patients: Subtype-Specific IL-6 Family Cytokine-Mediated VEGF Secretion 1 2

doi: 10.1016/j.tranon.2018.10.004

Figure Lengend Snippet: Expression of cytokines or their receptors and VEGF appears to affect survival in HER2- but not HER2+ subtypes. Kaplan–Meier survival curves of invasive ductal breast carcinoma for A) HER2- and HER2+ patients by IL-6 and VEGF expression. In HER2- patients, high IL-6 and high VEGF expression (upper quartiles, respectively) is strongly correlated with decreased survival when compared to patients with low IL-6 and low VEGF expression (lower quartiles, respectively). However, this trend is not evident in HER2+ individuals. Similar trends are observed in Kaplan–Meier survival curves between HER2- and HER2+ patients by B) IL-6Rα and VEGF expression and C) LIF and VEGF expression. D) Co-expression of LIFRβ and VEGF does not significantly affect survival in either HER2- or HER2+ patients. Analysis obtained from Oncomine dataset entitled Curtis Breast. Log-rank test * P < .05, ** P < .01, *** P < .001.

Article Snippet: Analysis of VEGF secretion in the conditioned media (CM) of MDA-MB-231, T47D, MCF7, SK-BR-3, MDA-MB-453, and BT474 (ATCC, Manassas, VA) breast cancer cells was assessed via VEGF ELISA according to the manufacturer's protocol (Cat# Dy293B, R&D Systems, Bethesda, MD).

Techniques: Expressing

Journal: Translational Oncology

Article Title: Co-Expression of VEGF and IL-6 Family Cytokines is Associated with Decreased Survival in HER2 Negative Breast Cancer Patients: Subtype-Specific IL-6 Family Cytokine-Mediated VEGF Secretion 1 2

doi: 10.1016/j.tranon.2018.10.004

Figure Lengend Snippet: Co-expression of OSM or OSMRβ and VEGF differentially affects survival based on estrogen receptor status. Kaplan–Meier survival curves of invasive ductal breast carcinoma for A) HER2−/ER- and HER2+/ER- patients and B) HER2−/ER+ and HER2+/ER+ patients by OSM and VEGF expression. In patients with either HER2+/− and ER- expression, OSM/VEGF expression levels do not significantly affect survival. However, in HER2−/ER+ patients, high OSM and high VEGF expression (upper quartiles, respectively) is strongly correlated with decreased survival when compared to patients with similar receptor status expressing low OSM and low VEGF expression (lower quartiles, respectively). Similar trends respective of receptor status are observed in Kaplan–Meier survival curves for C) HER2−/ER- and HER2+/ER- patients and D) HER2−/ER+ and HER2+/ER+ patients by OSMRβ and VEGF expression. While no correlation between OSM/VEGF expression and survival is observed in HER2+/ER+ patients, the low number of samples in these populations distorts our ability to make a robust assessment of this patient subset. Analysis obtained from Oncomine dataset entitled Curtis Breast. Log-rank test * P < .05, ** P < .01.

Article Snippet: Analysis of VEGF secretion in the conditioned media (CM) of MDA-MB-231, T47D, MCF7, SK-BR-3, MDA-MB-453, and BT474 (ATCC, Manassas, VA) breast cancer cells was assessed via VEGF ELISA according to the manufacturer's protocol (Cat# Dy293B, R&D Systems, Bethesda, MD).

Techniques: Expressing

Journal: Biotechnology letters

Article Title: Ultrasensitive immuno-detection using viral nanoparticles with modular assembly using genetically-directed biotinylation

doi: 10.1007/s10529-014-1555-9

Figure Lengend Snippet: VEGF (26 aM - 2.6 pM) was spiked into 50% BAL fluid (in PBS), and incubated with polyclonal anti-VEGF antibody functionalized magnetic particles. The biotinylated antibody/Neutravidin/phage affinity reagent was added, followed by washing. The sample was then analyzed using real-time PCR with phage-specific primers (n=6, error bars = ±1 SD, Non-template control Ct ≥34). The No-VEGF control (Ct =22.67±0.55) is shown as a solid line with +/− one standard deviation represented by dotted lines.

Article Snippet: The particles were washed, resuspended in coating buffer (1×10 7 particles in 1 ml 0.1 M sodium borate, pH 9.5) and mixed with 240 μl polyclonal anti-human Vascular Endothelial Growth Factor (VEGF) antibody (1 mg/ml, AB-293-NA, R&D Systems) and 240 μl 3 M (NH 4 ) 2 SO 4 .

Techniques: Incubation, Real-time Polymerase Chain Reaction, Control, Standard Deviation

Journal: PLoS ONE

Article Title: Combined Inhibition of Epidermal Growth Factor Receptor and Cyclooxygenase-2 Leads to Greater Anti-tumor Activity of Docetaxel in Advanced Prostate Cancer

doi: 10.1371/journal.pone.0076169

Figure Lengend Snippet: Cells grown in 1% FBS were exposed to 0.01 μmol/L docetaxel (D), 20 μmol/L gefitinib (G) or100 μmol/LNS-398 (N), alone or in combination, or with DMSO as control for 24 h. NF-KB, MMP-9 and VEGF mRNA (A and B) and protein levels (C and D) were measured as described in Materials and Methods. Values are reported as the mean±SD of three independent experiments.

Article Snippet: Antibodies against human VEGF and MMP-9 were obtained from R&D System and Bioworld, respectively.

Techniques: Control